Press Enter to search · Esc to close
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.
The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.
A fresh systematic review consolidates the perioperative signals — delayed gastric emptying, hypoglycemia, anesthesia risk — that every patient on a GLP-1 should bring up before surgery.
The same peptide class everyone's whispering about in the locker room is showing up in neurology, nephrology, and orthopedic data. The signal looks real — but moderate, not miraculous.
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.
Weekly semaglutide rewrote metabolic medicine. The pipeline behind it — a small-molecule pill, a twin-receptor agonist, and an injectable depot that lasts weeks — is now coming into focus.